These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

403 related items for PubMed ID: 24588963

  • 1. Discovery of 3-(4-methanesulfonylphenoxy)-N-[1-(2-methoxy-ethoxymethyl)-1H-pyrazol-3-yl]-5-(3-methylpyridin-2-yl)-benzamide as a novel glucokinase activator (GKA) for the treatment of type 2 diabetes mellitus.
    Park K, Lee BM, Hyun KH, Lee DH, Choi HH, Kim H, Chong W, Kim KB, Nam SY.
    Bioorg Med Chem; 2014 Apr 01; 22(7):2280-93. PubMed ID: 24588963
    [Abstract] [Full Text] [Related]

  • 2. Discovery of a novel phenylethyl benzamide glucokinase activator for the treatment of type 2 diabetes mellitus.
    Park K, Lee BM, Kim YH, Han T, Yi W, Lee DH, Choi HH, Chong W, Lee CH.
    Bioorg Med Chem Lett; 2013 Jan 15; 23(2):537-42. PubMed ID: 23218712
    [Abstract] [Full Text] [Related]

  • 3. Pharmacokinetic and pharmacodynamic properties of the glucokinase activator MK-0941 in rodent models of type 2 diabetes and healthy dogs.
    Eiki J, Nagata Y, Futamura M, Sasaki-Yamamoto K, Iino T, Nishimura T, Chiba M, Ohyama S, Yoshida-Yoshimioto R, Fujii K, Hosaka H, Goto-Shimazaki H, Kadotani A, Ohe T, Lin S, Langdon RB, Berger JP.
    Mol Pharmacol; 2011 Dec 15; 80(6):1156-65. PubMed ID: 21937665
    [Abstract] [Full Text] [Related]

  • 4. Identification of YH-GKA, a novel benzamide glucokinase activator as therapeutic candidate for type 2 diabetes mellitus.
    Park K.
    Arch Pharm Res; 2012 Dec 15; 35(12):2029-33. PubMed ID: 23263798
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Glucokinase activator PSN-GK1 displays enhanced antihyperglycaemic and insulinotropic actions.
    Fyfe MC, White JR, Taylor A, Chatfield R, Wargent E, Printz RL, Sulpice T, McCormack JG, Procter MJ, Reynet C, Widdowson PS, Wong-Kai-In P.
    Diabetologia; 2007 Jun 15; 50(6):1277-87. PubMed ID: 17415548
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Novel, highly potent systemic glucokinase activators for the treatment of Type 2 Diabetes Mellitus.
    Xu J, Lin S, Myers RW, Addona G, Berger JP, Campbell B, Chen HS, Chen Z, Eiermann GJ, Elowe NH, Farrer BT, Feng W, Fu Q, Kats-Kagan R, Kavana M, Malkani S, McMasters DR, Mitra K, Pachanski MJ, Tong X, Trujillo ME, Xu L, Zhang B, Zhang F, Zhang R, Parmee ER.
    Bioorg Med Chem Lett; 2017 May 01; 27(9):2069-2073. PubMed ID: 28284804
    [Abstract] [Full Text] [Related]

  • 13. Discovery of (S)-6-(3-cyclopentyl-2-(4-(trifluoromethyl)-1H-imidazol-1-yl)propanamido)nicotinic acid as a hepatoselective glucokinase activator clinical candidate for treating type 2 diabetes mellitus.
    Pfefferkorn JA, Guzman-Perez A, Litchfield J, Aiello R, Treadway JL, Pettersen J, Minich ML, Filipski KJ, Jones CS, Tu M, Aspnes G, Risley H, Bian J, Stevens BD, Bourassa P, D'Aquila T, Baker L, Barucci N, Robertson AS, Bourbonais F, Derksen DR, Macdougall M, Cabrera O, Chen J, Lapworth AL, Landro JA, Zavadoski WJ, Atkinson K, Haddish-Berhane N, Tan B, Yao L, Kosa RE, Varma MV, Feng B, Duignan DB, El-Kattan A, Murdande S, Liu S, Ammirati M, Knafels J, Dasilva-Jardine P, Sweet L, Liras S, Rolph TP.
    J Med Chem; 2012 Feb 09; 55(3):1318-33. PubMed ID: 22196621
    [Abstract] [Full Text] [Related]

  • 14. Effect of 1-[4- [2-(4-bromobenzenesulfonamino) ethyl] phenylsulfonyl]-3-(trans-4-methylcyclohexyl)urea (I4), a new synthetic sulfonylurea compound, on glucose metabolism in vivo and in vitro.
    Wu GZ, Hong G, Zhang WP, Zhang HB.
    Arzneimittelforschung; 2009 Feb 09; 59(11):550-6. PubMed ID: 20066963
    [Abstract] [Full Text] [Related]

  • 15. Discovery, structure-activity relationships, pharmacokinetics, and efficacy of glucokinase activator (2R)-3-cyclopentyl-2-(4-methanesulfonylphenyl)-N-thiazol-2-yl-propionamide (RO0281675).
    Haynes NE, Corbett WL, Bizzarro FT, Guertin KR, Hilliard DW, Holland GW, Kester RF, Mahaney PE, Qi L, Spence CL, Tengi J, Dvorozniak MT, Railkar A, Matschinsky FM, Grippo JF, Grimsby J, Sarabu R.
    J Med Chem; 2010 May 13; 53(9):3618-25. PubMed ID: 20405948
    [Abstract] [Full Text] [Related]

  • 16. Antidiabetic potential of a novel dual-target activator of glucokinase and peroxisome proliferator activated receptor-γ.
    Lei L, Liu Q, Liu S, Huan Y, Sun S, Chen Z, Li L, Feng Z, Li Y, Shen Z.
    Metabolism; 2015 Oct 13; 64(10):1250-61. PubMed ID: 26189598
    [Abstract] [Full Text] [Related]

  • 17. SAR, pharmacokinetics, safety, and efficacy of glucokinase activating 2-(4-sulfonylphenyl)-N-thiazol-2-ylacetamides: discovery of PSN-GK1.
    Bertram LS, Black D, Briner PH, Chatfield R, Cooke A, Fyfe MC, Murray PJ, Naud F, Nawano M, Procter MJ, Rakipovski G, Rasamison CM, Reynet C, Schofield KL, Shah VK, Spindler F, Taylor A, Turton R, Williams GM, Wong-Kai-In P, Yasuda K.
    J Med Chem; 2008 Jul 24; 51(14):4340-5. PubMed ID: 18588279
    [Abstract] [Full Text] [Related]

  • 18. A novel glucokinase activator modulates pancreatic islet and hepatocyte function.
    Efanov AM, Barrett DG, Brenner MB, Briggs SL, Delaunois A, Durbin JD, Giese U, Guo H, Radloff M, Gil GS, Sewing S, Wang Y, Weichert A, Zaliani A, Gromada J.
    Endocrinology; 2005 Sep 24; 146(9):3696-701. PubMed ID: 15919746
    [Abstract] [Full Text] [Related]

  • 19. Discovery of potent and orally active 1,4-disubstituted indazoles as novel allosteric glucokinase activators.
    Cheruvallath ZS, Gwaltney SL, Sabat M, Tang M, Wang H, Jennings A, Hosfield D, Lee B, Wu Y, Halkowycz P, Grimshaw CE.
    Bioorg Med Chem Lett; 2017 Jun 15; 27(12):2678-2682. PubMed ID: 28512030
    [Abstract] [Full Text] [Related]

  • 20. Discovery of liver-directed glucokinase activator having anti-hyperglycemic effect without hypoglycemia.
    Deshpande AM, Bhuniya D, De S, Dave B, Vyavahare VP, Kurhade SH, Kandalkar SR, Naik KP, Kobal BS, Kaduskar RD, Basu S, Jain V, Patil P, Chaturvedi Joshi S, Bhat G, Raje AA, Reddy S, Gundu J, Madgula V, Tambe S, Shitole P, Umrani D, Chugh A, Palle VP, Mookhtiar KA.
    Eur J Med Chem; 2017 Jun 16; 133():268-286. PubMed ID: 28390958
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.